Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/16/2026, 6:06:28 AM
Content snapshot
{ "session_id": "sess_SDA-2026-04-14-gap-pubmed-20260410-181258-df5eee45", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "minimax:MiniMax-M2.7", "action": "synthesize", "content": "\n\n# Synthesis Output: Microglial Phagocytosis of LC Axons in Early AD\n\n```json\n{\n \"ranked_hypotheses\": [\n {\n \"rank\": 1,\n \"hypothesis_id\": \"H1\",\n \"title\": \"Complement C1q/C3 Tagging of Vulnerable LC Axons\",\n \"target\": \"C1q/C3-CR3 axis\",\n \"composite_score\": 0.69,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.75,\n \"evidence_strength\": 0.80,\n \"novelty\": 0.50,\n \"feasibility\": 0.70,\n \"therapeutic_potential\": 0.75,\n \"druggability\": 0.85,\n \"safety_profile\": 0.40,\n \"competitive_landscape\": 0.70,\n \"data_availability\": 0.75,\n \"reproducibility\": 0.70\n },\n \"evidence_for\": [\n {\n \"claim\": \"Complement C1q initiates chronic microglia-mediated synapse loss in early AD\",\n \"pmid\": \"27280390\"\n },\n {\n \"claim\": \"C1q binds to stressed neurons and triggers complement-dependent phagocytosis\",\n \"pmid\": \"28854263\"\n },\n {\n \"claim\": \"Complement-dependent synapse loss precedes amyloid plaques in AD mouse models\",\n \"pmid\": \"29053648\"\n },\n {\n \"claim\": \"ANX-005 (Annexon) demonstrates acceptable safety in Phase 2 for GBS\",\n \"pmid\": \"NCT04798656\"\n },\n {\n \"claim\": \"Pegcetacoplan (C3 inhibitor) approved for PNH with good safety profile\",\n \"pmid\": \"NCT04123945\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"C1q deficiency paradoxically worsens some neurodegenerative phenotypes\",\n \"pmid\": \"23115156\"\n },\n {\n \"claim\": \"C3 deletion does not universally prevent synaptic loss; redundancy in phagocytic pathways\",\n \"pmid\": \"28662915\"\n },\n {\n \"claim\": \"Regional complement expression varies; OB complement dynamics unproven\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"CR3 specifically recognizes LC-derived complement opsonins versus other synaptic populations remains untested\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"C1q must colocalize with LC terminals (DBH+) in pre-symptomatic AD tissue\",\n \"Regional specificity of complement activation at LC-olfactory bulb interface unproven\",\n \"Systemic complement inhibition carries infection risk - intranasal delivery required\"\n ],\n \"recommended_validation\": \"C1q immunostaining combined with DBH marking in pre-symptomatic AD olfactory bulb tissue\",\n \"therapeutic_strategy\": \"Intranasal delivery of ANX-005 or novel C1q inhibitor to achieve local inhibition without systemic suppression\"\n },\n {\n \"rank\": 2,\n \"hypothesis_id\": \"H7\",\n \"title\": \"APOE4-Driven Microglial Response Creates Lipid-Enriched Environment Promoting LC Axon Engulfment\",\n \"target\": \"APOE/LXR pathway\",\n \"composite_score\": 0.65,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.65,\n \"evidence_strength\": 0.70,\n \"novelty\": 0.55,\n \"feasibility\": 0.70,\n \"therapeutic_potential\": 0.75,\n \"druggability\": 0.70,\n \"safety_profile\": 0.55,\n \"competitive_landscape\": 0.60,\n \"data_availability\": 0.65,\n \"reproducibility\": 0.65\n },\n \"evidence_for\": [\n {\n \"claim\": \"APOE4 drives microglial lipid accumulation and inflammatory activation\",\n \"pmid\": \"30242312\"\n },\n {\n \"claim\": \"ABCA1 deletion enhances amyloid deposition and memory deficits in AD mice\",\n \"pmid\": \"19118129\"\n },\n {\n \"claim\": \"APOE regulates neuronal lipid homeostasis and axonal integrity\",\n \"pmid\": \"28467879\"\n },\n {\n \"claim\": \"CN-105 (APOE4 peptide modulator) completed Phase 1 with acceptable safety\",\n \"pmid\": \"NCT03822659\"\n },\n {\n \"claim\": \"RGX-104 (LXR agonist) Phase 1 completed establishing preliminary safety\",\n \"pmid\": \"NCT03504761\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"APOE4 effects are global, not LC-specific; microglial lipid accumulation occurs systemically\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"CN-105 failed primary endpoints in mild-to-moderate AD (Phase 2)\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"LXR agonists show hepatic steatosis and triglyceride elevation\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"LC axons not demonstrably lipid-rich compared to other neuronal populations\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"LC-specific lipid accumulation in APOE4 carriers needs demonstration\",\n \"CN-105 failure in established AD may not predict failure in pre-symptomatic intervention\",\n \"Microglial lipid accumulation may be protective (storage of toxic species) rather than priming for phagocytosis\"\n ],\n \"recommended_validation\": \"Mass spectrometry comparing lipidomes of LC vs non-LC terminals in APOE4 vs APOE3 human brain tissue\",\n \"therapeutic_strategy\": \"Reframe toward pre-symptomatic intervention with CN-105 or LXR agonists optimized for CNS penetration\"\n },\n {\n \"rank\": 3,\n \"hypothesis_id\": \"H3\",\n \"title\": \"TREM2-Driven Microglial State Transition Triggers Synapse-Specific LC Axon Engulfment\",\n \"target\": \"TREM2 signaling pathway\",\n \"composite_score\": 0.60,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.50,\n \"evidence_strength\": 0.65,\n \"novelty\": 0.60,\n \"feasibility\": 0.70,\n \"therapeutic_potential\": 0.70,\n \"druggability\": 0.80,\n \"safety_profile\": 0.55,\n \"competitive_landscape\": 0.65,\n \"data_availability\": 0.60,\n \"reproducibility\": 0.55\n },\n \"evidence_for\": [\n {\n \"claim\": \"TREM2 deficiency impairs microglia survival and accelerates neurodegeneration\",\n \"pmid\": \"32106183\"\n },\n {\n \"claim\": \"TREM2 drives disease-associated microglia program around amyloid plaques\",\n \"pmid\": \"29463701\"\n },\n {\n \"claim\": \"TREM2 variants alter microglial responses to neurodegeneration\",\n \"pmid\": \"29195063\"\n },\n {\n \"claim\": \"AL002 (TREM2 agonist) in Phase 1 for AD with partner AbbVie\",\n \"pmid\": \"NCT04605190\"\n },\n {\n \"claim\": \"TREM2 agonists (MITG, ABT-981) improve AD outcomes in preclinical models\",\n \"pmid\": \"32444695\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"TREM2 deficiency accelerates neurodegeneration in multiple models - opposite of hypothesis\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"TREM2 agonists improve AD outcomes - therapeutic direction should be agonism not antagonism\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"DAM program lacks synaptic specificity; Apoe, Lpl, Clec7a are lipid processing genes\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"TREM2 may be response to LC pathology rather than trigger; conflates correlation with causation\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"Hypothesis requires partial inhibition (not complete knockout) - unresolved therapeutic window\",\n \"DAM program enhances general debris clearance, not LC-specific recognition\",\n \"TREM2 may be downstream of LC degeneration creating self-reinforcing cycle\"\n ],\n \"recommended_validation\": \"Single-cell RNA-seq of OB microglia in early AD comparing Trem2-/- vs WT profiles\",\n \"therapeutic_strategy\": \"REFRAME: Use TREM2 agonism (AL002) to enhance microglial survival/fitness, preventing compensatory over-pruning when microglia are stressed - partner with Alector for olfactory bulb endpoints\"\n },\n {\n \"rank\": 4,\n \"hypothesis_id\": \"H4\",\n \"title\": \"P2Y6 Receptor Activation by Stress-Induced UDP Release from LC Axons\",\n \"target\": \"P2RY6 (P2Y6)\",\n \"composite_score\": 0.50,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.55,\n \"evidence_strength\": 0.60,\n \"novelty\": 0.55,\n \"feasibility\": 0.65,\n \"therapeutic_potential\": 0.50,\n \"druggability\": 0.70,\n \"safety_profile\": 0.55,\n \"competitive_landscape\": 0.35,\n \"data_availability\": 0.55,\n \"reproducibility\": 0.60\n },\n \"evidence_for\": [\n {\n \"claim\": \"P2Y6 receptor mediates microglial phagocytosis of stressed neurons via UDP recognition\",\n \"pmid\": \"17299618\"\n },\n {\n \"claim\": \"Pannexin-1 channels release ATP/UDP from neurons undergoing apoptosis\",\n \"pmid\": \"18640812\"\n },\n {\n \"claim\": \"P2Y6-dependent microglial recruitment to injured sites\",\n \"pmid\": \"23616844\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"P2Y6 activated by UDP from all damaged neurons - no LC specificity\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"P2Y6 antagonism in vivo shows limited effects - redundant find-me pathways exist\",\n \"pmid\": \"23392670\"\n },\n {\n \"claim\": \"LC neurons may not undergo acute apoptosis in early AD - kinetics mismatch\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"No clinical-stage P2Y6 antagonists exist\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"Spatial specificity implausible - UDP gradients from all damaged neurons compete\",\n \"UDP release requires apoptosis, but LC dysfunction is gradual not apoptotic-sudden\",\n \"No chemical matter beyond tool compounds (MRS2578, MRS2959)\"\n ],\n \"recommended_validation\": \"LC-specific pannexin-1 deletion using DIO-Cre; P2Y6 reporter mice imaging during AD progression\",\n \"therapeutic_strategy\": \"Deprioritize until LC-specific pannexin-1 deletion demonstrates UDP release from LC terminals\"\n },\n {\n \"rank\": 5,\n \"hypothesis_id\": \"H5\",\n \"title\": \"Phosphorylated Tau at LC Nucleus and Axons Triggers Microglial Recognition\",\n \"target\": \"Phospho-tau/TLR2/CD36/NLRP3\",\n \"composite_score\": 0.44,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.50,\n \"evidence_strength\": 0.55,\n \"novelty\": 0.55,\n \"feasibility\": 0.65,\n \"therapeutic_potential\": 0.60,\n \"druggability\": 0.65,\n \"safety_profile\": 0.55,\n \"competitive_landscape\": 0.60,\n \"data_availability\": 0.55,\n \"reproducibility\": 0.55\n },\n \"evidence_for\": [\n {\n \"claim\": \"Tau triggers microglial inflammatory activation via TLR2 and NLRP3\",\n \"pmid\": \"30106381\"\n },\n {\n \"claim\": \"Phospho-tau accumulation in LC precedes olfactory dysfunction in human AD\",\n \"pmid\": \"32994275\"\n },\n {\n \"claim\": \"Microglial CD36 mediates uptake of tau aggregates\",\n \"pmid\": \"30021874\"\n },\n {\n \"claim\": \"Multiple tau antibodies in clinical development (E2814, JNJ-63735957)\",\n \"pmid\": \"NCT05254058\"\n },\n {\n \"claim\": \"NLRP3 inhibitors in Phase 2 (dapansutrile, OLT1177)\",\n \"pmid\": \"NCT04494898\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"Tau pathology is global, not LC-specific - why microglia target LC over cortical projections\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"Tau deletion does not prevent LC degeneration in models\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"Tau immunotherapy effects on LC axons are unknown\",\n \"pmid\": \"31900329\"\n },\n {\n \"claim\": \"NLRP3 knockout shows minimal effect on early synapse loss independent of tau\",\n \"pmid\": \"34856665\"\n },\n {\n \"claim\": \"Cannot distinguish pathologically vs physiologically phosphorylated tau\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"Tau accumulation in LC may be consequence of metabolic stress, not cause of phagocytosis\",\n \"LC neurons have high firing rate requiring constant tubulin modification - normal vs pathological tau unclear\",\n \"Tau antibodies failed multiple Phase 2 trials (gosuranemab, semorinemab, tilavonemab)\"\n ],\n \"recommended_validation\": \"LC-specific tau S262A mutation to prevent phosphorylation; microglia TLR2/CD36 conditional knockout in OB\",\n \"therapeutic_strategy\": \"Focus on NLRP3 as downstream target with acceptable safety profile - tau upstream requires validation\"\n },\n {\n \"rank\": 6,\n \"hypothesis_id\": \"H2\",\n \"title\": \"Fractalkine (CX3CL1/CX3CR1) Signaling Deficiency Enables Aberrant LC Axon Pruning\",\n \"target\": \"CX3CL1/CX3CR1 axis\",\n \"composite_score\": 0.41,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.55,\n \"evidence_strength\": 0.65,\n \"novelty\": 0.50,\n \"feasibility\": 0.65,\n \"therapeutic_potential\": 0.60,\n \"druggability\": 0.75,\n \"safety_profile\": 0.50,\n \"competitive_landscape\": 0.55,\n \"data_availability\": 0.60,\n \"reproducibility\": 0.55\n },\n \"evidence_for\": [\n {\n \"claim\": \"CX3CR1 deficiency exacerbates amyloid pathology and cognitive decline in 5xFAD mice\",\n \"pmid\": \"21454087\"\n },\n {\n \"claim\": \"CX3CL1-CX3CR1 signaling regulates microglial activation and neuroprotection\",\n \"pmid\": \"15590687\"\n },\n {\n \"claim\": \"Neuronal CX3CL1 suppresses neurotoxic microglial activation\",\n \"pmid\": \"17197703\"\n },\n {\n \"claim\": \"AZD8797 (CX3CR1 antagonist) completed Phase 1 with acceptable safety\",\n \"pmid\": \"NCT01654510\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"CRITICAL FLAW: CX3CR1 deficiency is harmful (exacerbates pathology) but hypothesis proposes ligand downregulation drives pathology - inconsistent with evidence\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"CX3CL1 overexpression paradoxically worsens outcomes in ALS models\",\n \"pmid\": \"29624974\"\n },\n {\n \"claim\": \"CX3CR1 knockout effects are context and stage dependent - complex outcomes\",\n \"pmid\": \"31439797\"\n },\n {\n \"claim\": \"Direct measurement of LC neuronal CX3CL1 in early AD not performed - downregulation inferred not demonstrated\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"CX3CL1 is expressed broadly - no mechanism for selective LC downregulation\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"Logical inversion: if receptor deficiency is harmful, ligand reduction should also be harmful\",\n \"No direct evidence of LC-specific CX3CL1 downregulation in early AD\",\n \"Mechanism assumes reduced fractalkine engages developmental-style pruning without explaining how\"\n ],\n \"recommended_validation\": \"TRAP sequencing from LC-specific reporter mice crossed to APP/PS1 - measure Cx3cl1 mRNA at 2, 4, 6 months\",\n \"therapeutic_strategy\": \"Abandon as currently framed; revisit only if LC-specific CX3CL1 downregulation is demonstrated\"\n },\n {\n \"rank\": 7,\n \"hypothesis_id\": \"H6\",\n \"title\": \"Prostaglandin E2/EP2 Receptor Axis Programs Microglia for Synaptogenic Phagocytosis\",\n \"target\": \"EP2 receptor (PTGER2)/COX-2/PGE2 axis\",\n \"composite_score\": 0.33,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.35,\n \"evidence_strength\": 0.45,\n \"novelty\": 0.45,\n \"feasibility\": 0.60,\n \"therapeutic_potential\": 0.40,\n \"druggability\": 0.60,\n \"safety_profile\": 0.45,\n \"competitive_landscape\": 0.30,\n \"data_availability\": 0.50,\n \"reproducibility\": 0.45\n },\n \"evidence_for\": [\n {\n \"claim\": \"PGE2-EP4 signaling promotes neuroinflammation and accelerates AD pathology\",\n \"pmid\": \"31138675\"\n },\n {\n \"claim\": \"EP2 deficiency reduces neuroinflammation and improves cognitive outcomes in AD models\",\n \"pmid\": \"29163316\"\n },\n {\n \"claim\": \"COX-2 expression in glial cells precedes plaque formation in AD brain\",\n \"pmid\": \"16437551\"\n },\n {\n \"claim\": \"PF-04418948 (EP2 antagonist) Phase 1 completed establishing preliminary safety\",\n \"pmid\": \"NULL\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"Lowest confidence hypothesis - mechanism lacks LC specificity entirely\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"PGE2 acts volume-transmitted throughout brain - no anatomical selectivity\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"EP2 deletion effects are not region-specific - improves cognition globally\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"COX-2 elevation is general injury response - no specific LC targeting\",\n \"pmid\": \"NULL\"\n },\n {\n \"claim\": \"PGE2 has protective roles in some contexts; global modulation may have off-target effects\",\n \"pmid\": \"17258583\"\n },\n {\n \"claim\": \"No active CNS-focused EP2 antagonist development programs\",\n \"pmid\": \"NULL\"\n }\n ],\n \"key_uncertainties\": [\n \"Weakest hypothesis with insufficient mechanistic support\",\n \"No evidence EP2 activation preferentially drives LC phagocytosis over other monoaminergic terminals\",\n \"Link between EP2 activation and complement upregulation in OB microglia unestablished\"\n ],\n \"recommended_validation\": \"EP2 conditional knockout in OB microglia only using Cx3cr1-CreER\",\n \"therapeutic_strategy\": \"Deprioritize - insufficient evidence to justify drug development investment\"\n }\n ],\n \"top_3_for_investigation\": [\n {\n \"rank\": 1,\n \"hypothesis_id\": \"H1\",\n \"title\": \"Complement C1q/C3 Tagging of Vulnerable LC Axons\",\n \"rationale\": \"Highest composite score (0.69), strongest mechanistic evidence, ANX-005 and Pegcetacoplan available as clinical assets, intranasal delivery addresses safety concerns\",\n \"immediate_action\": \"Dual immunostaining for C1q and DBH in pre-symptomatic AD olfactory bulb tissue (N=20 cases) - $50K, 3 months\"\n },\n {\n \"rank\": 2,\n \"hypothesis_id\": \"H7\",\n \"title\": \"APOE4-Driven Microglial Response Creates Lipid-Enriched Environment Promoting LC Axon Engulfment\",\n \"rationale\": \"Second highest score (0.65), strong genetic and biochemical evidence, CN-105 has Phase 1 safety data, pre-symptomatic intervention window may overcome Phase 2 failure\",\n \"immediate_action\": \"Mass spectrometry lipidomics of laser-captured LC vs non-LC terminals from APOE4 vs APOE3 postmortem tissue - $30K, 4 months\"\n },\n {\n \"rank\": 3,\n \"hypothesis_id\": \"H3\",\n \"title\": \"TREM2-Driven Microglial State Transition\",\n \"rationale\": \"Third highest score (0.60), requires therapeutic direction reframing (agonism not antagonism), AL002 in Phase 1 enables rapid clinical validation with OB endpoints\",\n \"immediate_action\": \"Partner with Alector to add olfactory bulb MRI and olfactory testing to ongoing AL002 Phase 1 trial - academic contribution to industry study\"\n }\n ],\n \"knowledge_edges\": [\n {\n \"source\": \"LCneurons\",\n \"edge_type\": \"express\",\n \"target\": \"DBH\",\n \"weight\": 0.95,\n \"citation\": \"PMID:32994275\"\n },\n {\n \"source\": \"LCneurons\",\n \"edge_type\": \"secrete\",\n \"target\": \"norepinephrine\",\n \"weight\": 0.95,\n \"citation\": \"PMID:32994275\"\n },\n {\n \"source\": \"StressedLCaxons\",\n \"edge_type\": \"bind\",\n \"target\": \"C1q\",\n \"weight\": 0.80,\n \"citation\": \"PMID:28854263\"\n },\n {\n \"source\": \"C1q\",\n \"edge_type\": \"activates\",\n \"target\": \"C3\",\n \"weight\": 0.85,\n \"citation\": \"PMID:27280390\"\n },\n {\n \"source\": \"C3\",\n \"edge_type\": \"opsonizes\",\n \"target\": \"LCaxons\",\n \"weight\": 0.75,\n \"citation\": \"PMID:29053648\"\n },\n {\n \"source\": \"Microglia_CR3\",\n \"edge_type\": \"recognizes\",\n \"target\": \"C3-opsonized_targets\",\n \"weight\": 0.80,\n \"citation\": \"PMID:29053648\"\n },\n {\n \"source\": \"Microglia_CR3\",\n \"edge_type\": \"mediates\",\n \"target\": \"phagocytosis\",\n \"weight\": 0.85,\n \"citation\": \"PMID:27280390\"\n },\n {\n \"source\": \"LCneurons\",\n \"edge_type\": \"express\",\n \"target\": \"CX3CL1\",\n \"weight\": 0.70,\n \"citation\": \"PMID:17197703\"\n },\n {\n \"source\": \"CX3CL1\",\n \"edge_type\": \"binds\",\n \"target\": \"Microglia_CX3CR1\",\n \"weight\": 0.85,\n \"citation\": \"PMID:15590687\"\n },\n {\n \"source\": \"CX3CR1_signaling\",\n \"edge_type\": \"suppresses\",\n \"target\": \"microglial_phagocytosis\",\n \"weight\": 0.70,\n \"citation\": \"PMID:21454087\"\n },\n {\n \"source\": \"CX3CR1_deficiency\",\n \"edge_type\": \"exacerbates\",\n \"target\": \"amyloid_pathology\",\n \"weight\": 0.80,\n \"citation\": \"PMID:21454087\"\n },\n {\n \"source\": \"StressedLC\",\n \"edge_type\": \"release\",\n \"target\": \"lipids\",\n \"weight\": 0.60,\n \"citation\": \"NULL\"\n },\n {\n \"source\": \"Microglia_TREM2\",\n \"edge_type\": \"recognizes\",\n \"target\": \"lipids\",\n \"weight\": 0.75,\n \"citation\": \"PMID:29195063\"\n },\n {\n \"source\": \"TREM2\",\n \"edge_type\": \"drives\",\n \"target\": \"DAM_program\",\n \"weight\": 0.85,\n \"citation\": \"PMID:29463701\"\n },\n {\n \"source\": \"TREM2_deficiency\",\n \"edge_type\": \"impairs\",\n \"target\": \"microglia_survival\",\n \"weight\": 0.80,\n \"citation\": \"PMID:32106183\"\n },\n {\n \"source\": \"DAM\",\n \"edge_type\": \"upregulates\",\n \"target\": \"phagocytic_machinery\",\n \"weight\": 0.65,\n \"citation\": \"PMID:29463701\"\n },\n {\n \"source\": \"StressedLC\",\n \"edge_type\": \"open_Pannexin1\",\n \"target\": \"UDP_release\",\n \"weight\": 0.55,\n \"citation\": \"PMID:18640812\"\n },\n {\n \"source\": \"UDP\",\n \"edge_type\": \"activates\",\n \"target\": \"Microglia_P2Y6\",\n \"weight\": 0.75,\n \"citation\": \"PMID:17299618\"\n },\n {\n \"source\": \"P", "tokens_used": "5641", "persona_id": "persona-synthesizer" }